Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EchoIQ Limited ( (AU:EIQ) ) has shared an announcement.
Echo IQ has announced the publication of a peer-reviewed analysis in the Journal of the American College of Cardiology Advances, highlighting the potential of their AI-based EchoSolv HF technology to improve the precision of heart failure diagnosis. The study demonstrated that the AI model can reliably identify left ventricular dysfunction, a key factor in heart failure, even with missing parameters. This advancement positions EchoSolv HF as a promising tool for physicians, potentially leading to better health outcomes and supporting further clinical validation and regulatory submission processes.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.38 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
More about EchoIQ Limited
Echo IQ is an AI and medical technology company specializing in clinical decision support solutions for heart failure. Their primary product, EchoSolv HF, utilizes an AI-based algorithm to enhance the precision of heart failure diagnosis, with a focus on improving health outcomes.
Average Trading Volume: 2,900,315
Technical Sentiment Signal: Hold
Current Market Cap: A$158.1M
Learn more about EIQ stock on TipRanks’ Stock Analysis page.